Hypothyroidism – the deficiency of thyroid hormones – is a common condition worldwide, affecting 5-10 % of the entire population. The disease is more prevalent in women than in men, and the vast majority of the patients are over the age of 40. The condition affects almost all body systems and thus presents a wide variety of clinical symptoms, including fatigue, depression, body weight gain, sensitivity to cold, hair loss, dry skin and anxiety.

Individuals with hypothyroidism range from being asymptomatic to, in rare cases, suffering from a life-threatening disease.

In healthy individuals, the thyroid gland predominantly secretes thyroxine (T4), which is then converted into triiodothyronine (T3). In hypothyroid patients, the levels of endogenous T4 and T3 are too low, and replacement therapy is needed.  Hypothyroid patients are most often treated with the synthetic hormone Levothyroxin. Although this is one of most frequently described drugs in the world, it comes with limited efficacy.

Our advanced formulation of T3 aims to provide an efficient and safe treatment alternative for the large and growing population suffering from hypothyroidism.